Uncategorized

Sun Pharma beams up Organon in $11.75B acquisition

Published

on

Sun Pharmaceutical is bringing Merck spinoff Organon into the fold, paying $11.75 billion in hopes of becoming a top global biosimilar player.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version